Given CBD’s reputation as a popular, artisanal remedy, one would think that Epidiolex would command a lot of “off label” attention. After all, physicians often prescribe pharmaceuticals off label to treat conditions that were not the actual focus of clinical trials. But the costly price tag for Epidiolex (more than $30,000 annually) precludes off label prescribing as well as affordable access for tens of millions of Americans without health insurance.

Another major reason why CBD oil has been positively received in some parts of the medical community is its apparent effect on cancer and tumor growth.A study done by the researchers of the Institute of Toxicology and Pharmacology, University of Rostock, Germany recommends the use of CBD oil (even direct injection into tumors) to eliminate or reduce the size of the tumors. The antioxidants in CBD hemp oil also provide anti-mutagenic properties and lower users’ risk of cancer.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160
×